Your SlideShare is downloading. ×
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Top 25 Ophtalmic Drug Manufacturers 2014-2024
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Top 25 Ophtalmic Drug Manufacturers 2014-2024

2,381

Published on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website …

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,381
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
74
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  • 2. Contents 1.1. Executive Summary Executive Summary 1.1 Leading Ophthalmic Drug Manufacturers: Overview of Findings 1.2 Chapter Breakdown 1.3 Research and Analysis Methods 1.4 Scope of this Report 1.5 Drugs Considered for this Report 1.6 Glossary of Terms in this Report 2.2. Introduction to the Ophthalmic Drugs Market Introduction to the Ophthalmic Drugs Market 2.1 The Eye: An Overview of Its Structure and Function 2.2 The Global Burden of Eye Disease 2.3 Ophthalmic Drugs: Market Segmentation 2.4 Glaucoma: the ‘Silent Thief of Sight’ 2.4.1 A Classification of Glaucoma 2.4.1.1 Primary Open-Angle Glaucoma 2.4.1.2 Acute Angle-Closure Glaucoma 2.4.1.3 Congenital Glaucoma 2.4.1.4 Secondary Glaucoma 2.4.1.5 Normal-Tension Glaucoma 2.4.1.6 Ocular Hypertension 2.4.2 Risk Factors for Glaucoma 2.4.3 Diagnosis of Glaucoma 2.4.4 Drug Treatment of Glaucoma www.visiongain.com
  • 3. Contents 2.4.5 Laser Treatment and Surgery for Glaucoma 2.5 Age-Related Macular Degeneration (AMD) 2.5.1 Dry (non-exudative) AMD 2.5.2 Wet (exudative) AMD 2.5.3 Risk Factors for AMD 2.5.4 Diagnosis of AMD 2.5.5 Treatment of AMD 2.6 Diabetic Retinopathy (DR) 2.6.1 Diagnosis of Diabetic Retinopathy 2.6.2 Treatment of Diabetic Retinopathy 2.7 Ocular Allergy and Allergic Conjunctivitis 2.7.1 Diagnosis of Ocular Allergy 2.7.2 Treatment of Ocular Allergy 2.8 Ocular Inflammatory Disease 2.8.1 Treatment of Ocular Inflammatory Disease 2.9 Eye Infections 2.9.1 Treatment of Eye Infections 2.10 Dry Eye Syndrome 2.10.1 Treatment of Dry Eye Syndrome 3.3. Ophthalmic Drugs: World Market 2014-2024 Ophthalmic Drugs: World Market 2014-2024 3.1 The World Ophthalmic Drugs Market in 2012 and 2013 3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024 3.3 Leading Ophthalmic Drugs www.visiongain.com
  • 4. Contents 3.4 Leading Companies in the Ophthalmic Drugs Market 3.4.1 Top 25 Ophthalmic Drug Manufacturers 2014-2024 3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2014-2024 3.5.1 Glaucoma Drugs Market: Sales Forecast 2014-2024 3.5.2 Retinal Disorders Drugs Market: Sales Forecast 2014-2024 3.5.3 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2014-2024 3.5.4 Dry Eye Drugs Market: Sales Forecast 2014-2024 3.6 Changing Market Shares by Segment 2014-2024 3.7 World Ophthalmic Drugs Market: Drivers and Restraints 4.4. Leading US Ophthalmic Drug Manufacturers in 2012 and 2013 Leading US Ophthalmic Drug Manufacturers in 2012 and 2013 4.1 Allergan 4.1.1 Allergan: Ophthalmic Product Portfolio 4.1.1.1 Restasis: Sales Forecast 2014-2024 4.1.1.2 Lumigan and Ganfort: Sales Forecast 2014-2024 4.1.1.3 Refresh Brand Products: Sales Forecast 2014-2024 4.1.1.4 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024 4.1.1.5 Acular: Sales Forecast 2014-2024 4.1.2 Allergan: Ophthalmic Product Pipeline 4.1.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema 4.1.2.2 Novadur (Intravitreal Brimonidine Implant) 4.1.2.3 AGN 208397 (Beclomethasone Intravitreal Injection) 4.1.2.4 Anti-VEGF DARPins (VEGF Inhibitors) www.visiongain.com
  • 5. Contents 4.1.3 Allergan: Ophthalmic Revenue Forecast 2014-2024 4.1.4 Allergan: SWOT Analysis 4.2 Merck 4.2.1 Merck: Ophthalmic Product Portfolio 4.2.1.1 Trusopt: Sales Forecast 2014-2024 4.2.1.2 Zioptan: Sales Forecast 2014-2024 4.2.1.3 AzaSite (azithromycin) 4.2.2 Merck: Ophthalmic Product Pipeline 4.2.3 Merck: Revenue Forecast 2014-2024 4.2.4 Merck: Drivers and Restraints 4.3 Pfizer 4.3.1 Pfizer: Ophthalmic Product Portfolio 4.3.1.1 Xalatan/Xalacom: Sales Forecast 2014-2024 4.3.1.2 Macugen (Valeant/Pfizer) 4.3.2 Pfizer: Ophthalmic Product Pipeline 4.3.3 Pfizer: Revenue Forecast 2014-2024 4.3.4 Pfizer: SWOT Analysis 4.4 Regeneron 4.4.1 Regeneron: Ophthalmic Product Portfolio 4.4.1.1 Eylea: US Sales Forecast 2014-2024 4.4.2 Regeneron: Ophthalmic Product Pipeline 4.4.3 Regeneron: Revenue Forecast 2014-2024 4.4.4 FDA Approves Zaltrap (aflibercept) 4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements www.visiongain.com
  • 6. Contents 4.4.6 Regeneron: SWOT Analysis 5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013 5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013 5.1 Novartis (including Alcon) 5.1.1 Novartis: Ophthalmic Product Portfolio 5.1.1.1 Lucentis (ranibizumab) 5.1.1.2 Lucentis: Non-US Sales Forecast 2014-2024 5.1.1.3 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024 5.1.1.4 Vigamox: Sales Forecast 2014-2024 5.1.1.5 Azopt: Sales Forecast 2014-2024 5.1.1.6 Jetrea: Non-US Sales Forecast 2014-2024 5.1.2 Novartis: Ophthalmic Product Pipeline 5.1.2.1 Lucentis (ranibizumab) For Myopic Choroidal Neovascularisation 5.1.2.2 Finafloxacin (MerLion Pharmaceuticals/Novartis) 5.1.2.3 AKB-9778 (Aerpio Therapeutics) 5.1.2.4 AL-78898A (Complement Factor Inhibitor, Alcon) 5.1.3 Novartis: Revenue Forecast 2014-2024 5.1.4 Novartis: SWOT Analysis 5.2 Roche 5.2.1 Roche: Ophthalmic Product Portfolio 5.2.1.1 Lucentis: US Sales Forecast 2014-2024 5.2.1.2 Avastin: Sales Forecast 2014-2024 5.2.2 Roche: Ophthalmic Product Pipeline 5.2.2.1 Lampalizumab (RG7417) www.visiongain.com
  • 7. Contents 5.2.3 Roche: Revenue Forecast 2014-2024 5.2.4 Roche: SWOT Analysis 6.6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in 2012 and 2013 2012 and 2013 6.1 Santen 6.1.1 Santen: Ophthalmic Product Portfolio 6.1.1.1 Eylea: Japan Sales Forecast 2014-2024 6.1.1.2 Hyalein: Sales Forecast 2014-2024 6.1.1.3 Cosopt: Japan Sales Forecast 2014-2024 6.1.1.4 Tapros/Taflotan: Sales Forecast 2014-2024 6.1.1.5 Diquas: Sales Forecast 2014-2024 6.1.1.6 Cravit and Tarivid: Sales Forecast 2014-2024 6.1.2 Santen: Ophthalmic Product Pipeline 6.1.3 Santen: Revenue Forecast 2014-2024 6.1.4 Santen Acquires Novagali Pharma 6.1.5 Santen: SWOT Analysis 6.2 Senju 6.2.1 Senju: Ophthalmic Product Portfolio 6.2.2 Senju: Ophthalmic Product Pipeline 6.2.2.1 Y-39983 (SNJ-1656) 6.2.2.2 Difluprednate (SJE-2079) 6.2.3 Senju: Revenue Forecast 2014-2024 6.2.4 Senju: SWOT Analysis 6.3 Valeant www.visiongain.com
  • 8. Contents 6.3.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion? 6.3.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals 6.3.3 Valeant: Ophthalmic Product Portfolio 6.3.3.1 Macugen (Valeant/Pfizer): A Drug in Decline 6.3.4 Valeant: Ophthalmic Product Pipeline 6.3.4.1 Latanoprostene Bunod (BOL-303259-X) 6.4.3.2 Mapracorat (BOL-303242-X) 6.3.5 Valeant: Revenue Forecast 2014-2024 6.3.6 Valeant: SWOT Analysis 7.7. Emerging Ophthalmic Drug Manufacturers in 2012 and 2013 Emerging Ophthalmic Drug Manufacturers in 2012 and 2013 7.1 Pipeline and Other Companies, 2012-2013 7.2 Notable Terminated Drug Candidates 7.3 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy 7.4 Acucela 7.5 Aerie Pharmaceuticals 7.6 Aerpio Therapeutics: Developing AKB-9778 7.7 Akorn 7.7.1 Cosopt/Cosopt PF: Sales Forecast 2014-2024 7.7.2 AzaSite: Sales Forecast 2014-2024 7.8 Alimera Sciences 7.8.1 Iluvien: Will It Gain FDA Approval? 7.8.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD 7.9 Altheos www.visiongain.com
  • 9. Contents 7.10 Amakem 7.11 Ampio Pharmaceuticals 7.12 Bayer 7.12.1 Eylea: non-US Sales Forecast 2014-2024 7.13 BioDiem 7.13.1 BDM-E: A High-Value Divestment? 7.14 Can-Fite BioPharma/OphthaliX 7.15 Chengdu Kanghong Pharmaceutical: Still Developing Conbercept? 7.16 Colby Pharmaceutical 7.16.1 CPC-551: A Potential Treatment for Geographic Atrophy in Dry AMD 7.17 Eleven Biotherapeutics 7.18 EyeGate Pharmaceuticals 7.19 Gene Signal 7.19.1 Aganirsen: Preventing Corneal Graft Rejection 7.19.2 GSK 7.19.3 Darapladib for Diabetic Macular Oedema 7.20 Icon Bioscience 7.21 Lpath 7.21.1 iSONEP: Antibodies Against Bioactive Lipids 7.22 MacuCLEAR 7.22.1 MC-1101: a Potential Therapy for Dry AMD 7.23 Neurotech 7.23.1 Renexus (NT-501) for Dry AMD 7.24 Omeros www.visiongain.com
  • 10. Contents 7.25 Ophthotech 7.25.1 Fovista: A Strong Competitor for the AMD Market 7.25.2 ARC1905: Complement C5 Inhibitor 7.25.3 Has Volociximab Been Terminated? 7.26 Otsuka Pharmaceutical 7.27 OXiGENE: Developing Zybrestat for Wet AMD 7.28 RXi Pharmaceuticals: Will Bevasiranib Resume Development? 7.29 Shire 7.29.1 Jerini Ophthalmic’s JSM6427 and JPE-1375 Terminated? 7.29.2 Lifitegrast (SHP606) for Dry Eye 7.29.3 Premiplex (SHP607): Preventing Retinopathy of Prematurity 7.30 Sirnaomics: Acurita (STP601) Still in Preclinical Development? 7.31 ThromboGenics 7.31.1 Jetrea (ocriplasmin) 7.31.1.1 Jetrea: US Sales Forecast 2014-2024 7.31.2 TB-403: Anti-Placental Growth Factor 8.8. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024 Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market 8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium] www.visiongain.com
  • 11. Contents 9.9. Research Interviews Research Interviews 9.1 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK 9.1.1 On the Role of VEGF in Retinal Disorders 9.1.2 On Candidate Molecule E10030 9.1.3 On Candidate Molecule JSM 6427 9.1.4 On New Sustained Release Formulations 9.1.5 On Delta-Notch Signalling 9.1.6 Potential Clinical Crossovers Between Ophthalmology and Oncology 9.1.7 Commercial and Clinical Possibilities in the Ophthalmology Market 9.1.8 On the Possibilities of Research into the Endothelial Fenestra 9.2 Expert Interview 2: Authority from a Company in the Industry (Views Provided Anonymously) 9.2.1 Key Unmet Needs 9.2.2 Challenges Facing the Ophthalmic Sector 9.2.3 On Current Ophthalmic Treatments and Their Effectiveness 9.2.4 On Opportunities in the Ophthalmic Sector 9.3 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, Michigan, USA 9.3.1 The Optogenetic Approach to Vision Restoration 9.3.2 Choosing Disease Targets and Delivery Vectors 9.3.3 The Regulatory Picture 9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas www.visiongain.com
  • 12. Contents 9.3.5 The Next Ten Years for Gene Therapy 9.4 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA 9.4.1 MC-1101: Identifying and Treating Chiou Syndrome 9.4.2 Preventing Dry AMD Progression 9.4.3 Treating the Root Cause of Dry AMD 9.4.4 Phase 3: Endpoints and Prospects for MC-1101 9.5 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA 9.5.1 The Impact of Eylea 9.5.2 The Comparative Dosing Schedules of Eylea and Lucentis 9.5.3 Patient Transitioning to Eylea: Salvage Switching 9.5.4 Avastin after the CATT Study 9.5.5 Prospects for Eylea in Other Indications and Combinations 9.5.6 Future Possibilities in Wet AMD Treatment 10. Conclusions 10. Conclusions 10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market 10.2 The World Ophthalmic Drugs Market in 2012 and 2013 10.2.1 Leading Ophthalmic Drugs Market Segments 10.2.2 Leading Ophthalmic Drugs 10.2.3 Leading Ophthalmic Drug Manufacturers 10.3 World Ophthalmic Drugs Market Forecast 2014-2024 10.4 The Future of the Ophthalmic Drugs Market? 10.4.1 Increasing Revenue Concentration among Specialist Companies 10.4.2 The Rise of Generics www.visiongain.com
  • 13. Contents 10.4.3 Small Companies Can Have a Big Impact 10.4.4 What Will Succeed in the Ophthalmic Drugs Market? List of Tables Table 1.1 Currency Exchange Rates, 2012 Table 2.1 ICD-10 Classification of Visual Impairment, 2010 Table 2.2 Drug Treatments for Glaucoma, 2013 Table 2.3 Drug Treatments for AMD, 2013 Table 2.4 Drug Treatments for Ocular Allergy, 2013 Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2013 Table 2.6 Selected Drug Treatments for Eye Infections, 2013 Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2012-2013 Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 20122024 Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), 2012-2013 Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Net Revenue ($m), Ophthalmic Drugs Revenue ($m), Market Share (%), 2012-2013 Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2013 Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2012-2018 Table 3.7 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2018-2024 Table 3.8 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024 www.visiongain.com
  • 14. Contents Table 3.9 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 20122024 Table 3.10 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024 Table 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024 Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2012, 2018 and 2024 Table 4.1 Allergan: Overview, 2012-2013 Table 4.2 Allergan: Ophthalmic Drug Products, 2013 Table 4.3 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2002-2012 Table 4.4 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.5 Allergan: Lumigan Revenue ($m), AGR (%), CAGR(%), 2000-2012 Table 4.6 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.7 Allergan: Refresh Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.8 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.10 Allergan: Revenues ($m) and Revenue Shares (%) by Region, 2012 Table 4.11 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.12 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 4.13 Merck: Overview, 2012-2013 Table 4.14 Merck: Trusopt Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.15 Merck: Zioptan Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.16 Merck: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.17 Pfizer: Overview, 2012-2013 www.visiongain.com
  • 15. Contents Table 4.18 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.19 Pfizer: Macugen Revenue ($m), AGR (%), CAGR(%), 2004-2012 Table 4.20 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.21 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 4.22 Regeneron: Overview, 2012-2013 Table 4.23 Regeneron: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.24 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 4.25 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 5.1 Novartis: Overview, 2012-2013 Table 5.2 Novartis: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.3 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR(%), 20122024 Table 5.4 Novartis: Vigamox Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.5 Novartis: Azopt Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.6 Novartis: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.7 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.8 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 5.9 Roche: Overview, 2012-2013 Table 5.10 Roche: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.11 Roche: Avastin Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.12 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 5.13 Roche: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 6.1 Santen: Overview, 2012-2013 Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, 2012-2013 Table 6.3 Santen: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024 www.visiongain.com
  • 16. Contents Table 6.4 Santen: Hyalein Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.5 Santen: Cosopt Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.7 Santen: Diquas Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.8 Santen: Cravit and Tarivid Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.9 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 6.11 Senju: Overview, 2012-2013 Table 6.12 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.13 Senju: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 6.14 Valeant: Overview, 2012-2013 Table 6.15 Valeant: Selected Products Revenue ($m), 2010-2012 Table 6.16 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 6.17 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Table 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 7.2 Akorn: AzaSite Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 7.3 Bayer: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024 Table 7.4 ThromboGenics: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024 www.visiongain.com
  • 17. Contents List of Figures Figure 2.1 Structure of the Human Eye Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2012 Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012 Figure 2.4 Classification of Glaucoma, 2013 Figure 3.1 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2012 Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2013 Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m), 2012-2024 Figure 3.4 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2013 Figure 3.5 Glaucoma Drugs Market Forecast: Revenues ($m), 2012-2024 Figure 3.6 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2012-2024 Figure 3.7 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), 20122024 Figure 3.8 Dry Eye Drugs Market Forecast: Revenues ($m), 2012-2024 Figure 3.9 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2018 Figure 3.10 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2024 Figure 3.11 World Ophthalmic Drugs Market: Drivers and Restraints, 2014-2024 Figure 4.1 Allergan: Restasis Revenue ($m), 2002-2012 Figure 4.2 Allergan: Restasis Revenue ($m), 2012-2024 Figure 4.3 Allergan: Lumigan Revenue ($m), 2000-2012 Figure 4.4 Allergan: Lumigan and Ganfort Revenue ($m), 2012-2024 Figure 4.5 Allergan: Refresh Revenue ($m), 2012-2024 Figure 4.6 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), 2012-2024 www.visiongain.com
  • 18. Contents Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024 Figure 4.8 Allergan: Revenue Shares (%) by Region, 2012 Figure 4.9 Allergan: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 4.10 Allergan: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 4.11 Merck: Trusopt Revenue ($m), 2012-2024 Figure 4.12 Merck: Zioptan Revenue ($m), 2012-2024 Figure 4.13 Merck: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 4.14 Merck: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 4.15 Merck: Drivers and Restraints, 2014-2024 Figure 4.16 Pfizer: Xalatan/Xalacom Revenue ($m), 2012-2024 Figure 4.17 Pfizer: Macugen Revenue ($m), 2004-2012 Figure 4.18 Pfizer: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 4.19 Pfizer: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 4.20 Regeneron: Eylea Revenue ($m), 2012-2024 Figure 4.21 Regeneron: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 4.22 Regeneron: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 5.1 Novartis: Lucentis Revenue ($m), 2012-2024 Figure 5.2 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), 2012-2024 Figure 5.3 Novartis: Vigamox Revenue ($m), 2012-2024 Figure 5.4 Novartis: Azopt Revenue ($m), 2012-2024 Figure 5.5 Novartis: Jetrea Revenue ($m), 2012-2024 Figure 5.6 Novartis: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 5.7 Novartis: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 5.8 Roche: Lucentis Revenue ($m), 2012-2024 www.visiongain.com
  • 19. Contents Figure 5.9 Roche: Avastin Revenue ($m), 2012-2024 Figure 5.10 Roche: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 5.11 Roche: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, 2012 Figure 6.2 Santen: Eylea Revenue ($m), 2012-2024 Figure 6.3 Santen: Hyalein Revenue ($m), 2012-2024 Figure 6.4 Santen: Cosopt Revenue ($m), 2012-2024 Figure 6.5 Santen: Tapros/Taflotan Revenue ($m), 2012-2024 Figure 6.6 Santen: Diquas Revenue ($m), 2012-2024 Figure 6.7 Santen: Cravit and Tarivid Revenue ($m), 2012-2024 Figure 6.8 Santen: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 6.9 Santen: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 6.10 Senju: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 6.11 Senju: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 6.12 Valeant: Ophthalmic Drugs Revenue ($m), 2012-2024 Figure 6.13 Valeant: Ophthalmic Drugs Market Share (%), 2012-2024 Figure 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), 2012-2024 Figure 7.2 Akorn: AzaSite Revenue ($m), 2012-2024 Figure 7.3 Alimera Sciences: Ophthalmic Drug Pipeline Progress, 2013 Figure 7.4 Bayer: Eylea Revenue ($m), 2012-2024 Figure 7.5 Gene Signal: Ophthalmic Drug Pipeline Progress, 2013 Figure 7.6 Neurotech: Ophthalmic Drug Pipeline Progress, 2013 Figure 7.7 Ophthotech: Ophthalmic Drug Pipeline Progress, 2013 Figure 7.8 Shire: Ophthalmic Drug Pipeline Progress, 2013 www.visiongain.com
  • 20. Contents Figure 7.9 ThromboGenics: Jetrea Revenue ($m), 2012-2024 Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2014-2024 Figure 10.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2013 Figure 10.2 World Ophthalmic Drugs Market: Revenues ($bn), 2012-2024 Figure 10.3 Leading Ophthalmic Drugs Manufactuters: Revenues ($m), 2012-2024 Companies Listed Abbott Laboratories (Abbott) Abbvie Acucela Advanced Vision Research (acquired by Akorn) Aerie Pharmaceuticals Aerpio Therapeutics Akorn Pharmaceuticals Alcon (subsidiary of Novartis) Alimera Sciences Allergan Allergro Ophthalmics Altheos Amakem Ampio Pharma Asahi Glass AstraZeneca Aton Pharma (acquired by Valeant) www.visiongain.com
  • 21. Contents Banyu Pharmaceutical (part of Merck) Bausch and Lomb (subsidiary of Valeant) Bayer Bayer Yakuhin (Japanese subsidiary of Bayer) BioDiem Biogen Idec BioInvent International Biovail Corporation (part of Valeant) Bristol-Myers Squibb Can-Fite BioPharma Chengdu Kanghong Pharmaceutical Chiron Corportation (part of Novartis) Chugai Pharmaceutical (part of Roche) CIBA VISION (part of Novartis) Ciba-Geigy (part of Novartis) Colby Pharmaceutical Company (Colby) CoMentis Daiichi Sankyo Eleven Biotherapeutics Eli Lilly and Company (Lilly) EyeGate Pharmaceuticals Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant) Fougera Pharmaceuticals (acquired by Novartis) Gene Signal www.visiongain.com
  • 22. Contents Genentech (subsidiary of Roche) Genzyme (subsidiary of Sanofi) Gilead Sciences GSK ICN Pharmaceuticals (original Valeant company) Icon Bioscience Inamed Corporation (subsidiary of Allergan) InSite Vision Inspire Pharmaceuticals (acquired by Merck) ISTA Pharmaceuticals (part of Valeant) Jerini AG Jerini Ophthalmic (part of Jerini AG) Johnson & Johnson Kestrel Ophthalmics Kyorin Pharmaceutical Kyowa Hakko Kirin LEO Pharma Lpath MacuCLEAR MacuSIGHT, Inc. MAP Pharmaceuticals (acquired by Allergan) Meda Medicis Corporation (acquired by Valeant) Merck & Co. (Merck) www.visiongain.com
  • 23. Contents MerLion Pharmaceuticals MSD K.K. (part of Merck) Mylan Pharmaceuticals Mystic Pharmaceuticals Neurotech NicOx Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim) NovaBay Pharmaceuticals Novagali Pharma (acquired by Santen) Novartis Novo (subsidiary of Novo Nordisk) Novo Nordisk Oakwood Laboratories OcuSciences Omeros Onyx Pharmaceuticals OphthaliX (part-owned by Can-Fite BioPharma) Ophthotech OPKO Health Ora OSI Pharmaceuticals Othera Pharmaceuticals (acquired by Colby) Otsuka Pharmaceutical Oxford BioMedica www.visiongain.com
  • 24. Contents OXiGENE Parke-Davis (subsidiary of Pfizer) PDL BioPharma Pfizer Pharmacia (acquired by Pfizer) Potentia Pharmaceuticals Premacure Procter & Gamble pSivida Quark Pharmaceuticals Reckitt Benckiser Regeneron RetroSense Therapeutics ReVision Therapeutics Roche RXi Pharmaceuticals Sandoz (part of Novartis) Sanofi Santen Pharmaceutical Co. (Santen) SARcode Bioscience Schering-Plough (part of Merck) Senju Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju) Senju USA Inc. (subsidiary of Senju) www.visiongain.com
  • 25. Contents Shire Sirion Therapeutics Sirna Therapeutics Sirnaomics SkinMedica (subsidiary of Allergan) Spark Therapeutics Symphony ViDA Takeda Pharmaceutical Teva The Patent Board ThromboGenics Upjohn (acquired by Pfizer through Pharmacia) Valeant Pharmaceuticals Ventana Medical Systems (acquired by Roche) Warburg Pincus LLC Warner-Lambert (acquired by Pfizer) Watson Pharmaceuticals Wyeth Pharmaceuticals (part of Pfizer) www.visiongain.com
  • 26. Contents Other Organisations Mentioned in This Report A*STAR Institute for Infocomm Research (Singapore) American Academy of Ophthalmology (AAO) American Diabetes Association American Society of Retina Specialists (ASRS) Association for Research in Vision and Ophthalmology (ARVO) Council of Europe Emory University European Medicines Agency (EMA) Foundation Fighting Blindness (FFB) (US) Health Canada Institute of Experimental Medicine (Russia) Institute of Ocular Pharmacology, Texas A&M (US) Institute of Ophthalmology, University College London (UK) Intellectual Property Appellate Board (India) International Diabetes Federation Internet Archive Japan Patent Office (JPO) Mayo Clinic Ministry of Health, Labour and Welfare (MHLW) (Japan) Monash University National Eye Institute (NEI) (US) National Health Service (NHS) (UK) National Institute for Health and Care Excellence (NICE) (UK) www.visiongain.com
  • 27. Contents NHS Scotland Novartis Institutes for BioMedical Research (NIBR) (part of Novartis) Novartis Venture Funds (NVF) (part of Novartis) Ophthalmology External Research Unit (part of Pfizer) Ophthrisi (GSK research unit) Rinat (Pfizer research unit) Texas Emerging Technology Fund Therapeutic Goods Administration (TGA) (Australia) Tokyo University of Science United States Food and Drug Administration (FDA) University of Florida University of Kentucky University of Melbourne University of Michigan US Preventive Services Task Force (USPSTF) US Securities and Exchange Commission (SEC) World Health Organization (WHO) www.visiongain.com
  • 28. Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 4.1.1.5 Acular: Sales Forecast 2014-2024 Acular (ketorolac tromethamine, Allergan) is a topical NSAID eyedrop solution, indicated in the relief of ocular itching due to seasonal allergic conjunctivitis and post-operative ocular inflammation. First launched in the Netherlands and Canada in 1992, it is now available in several other countries worldwide, including the UK, Germany and the US. New forms, Acular PF and Acular LS, have since received FDA approval and are also available in the US market. Visiongain estimates that sales of Acular had declined to $60m in 2012. We predict that sales will continue to decline further, reaching $33m in 2018 for a CAGR of -9.3% over 2012-2018. The US patent for ketorolac tromethamine expired in the fourth quarter of 2009 and generic versions of Acular are available. Sales will continue to fall from 2018 to 2024, reaching $26m in 2024 (Table 4.9 and Figure 4.7). This represents a CAGR of -4.2% over 2018-2024 and an overall CAGR of -6.8% over 2012-2024. Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024 Acular ($m) Annual Growth Rate (%) CAGR (%, 2012-2018 and 2018-2024) CAGR (%, 2012-2024) 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 60 54 48 44 39 36 33 31 30 28 27 26 26 -10.0 -10.0 -10.0 -10.0 -8.0 -8.0 -6.0 -5.0 -5.0 -3.0 -3.0 -3.0 -9.3 -4.2 -6.8 Source: visiongain 2013 Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024 70 60 60 Revenue ($m) 50 54 48 40 44 39 36 33 30 31 30 28 27 26 26 20 10 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Year Source: visiongain 2013 www.visiongain.com Page 84
  • 29. Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 • Warner-Lambert, acquired in 2000 for around $90bn. Warner-Lambert itself had become a major pharmaceutical player through mergers and acquisitions, having joined with ParkeDavis during the 1970s. • Pharmacia and its subsidiary Upjohn, acquired in April 2003 for $60bn. • Wyeth Pharmaceuticals, acquired in January 2009 for $68bn. This acquisition gave Pfizer access to additional ophthalmic products. The company is perhaps best known for its blockbuster drug Lipitor (atorvastatin), which lost patent protection in November 2011. In July 2011, Pfizer announced that it intended to focus on its core pharmaceutical business in the future and planned to divest its animal health and nutrition divisions. In April 2012, Nestlé acquired the company’s infant nutrition business and in January 2013, Pfizer’s Animal Health business became a separate company called Zoetis. Table 4.17 presents an overview of Pfizer. Table 4.17 Pfizer: Overview, 2012-2013 Ranking in 2013 (2012) Company Notable Subsidiaries Business Areas Established Headquarters FY 2012 Revenue ($m) FY2012 Ophthalmic Drugs Revenue ($m) Leading Ophthalmic Drugs Market Share, 2012 (%) Market Share, 2024 (%) 7 (7) Pfizer, Inc. Wyeth (2009) Pharmaceuticals, nutritionals, vaccines, consumer health 1849 New York City, New York, US 58,896 812 Xalatan/Xalacom, Macugen 4.5 0.7 Source: Company reports; visiongain 2013 4.3.1 Pfizer: Ophthalmic Product Portfolio Pfizer currently markets three ophthalmic products: Xalatan (latanoprost) and Xalacom (latanoprost/timolol) for glaucoma and Macugen (pegaptanib) for wet AMD. Both Xalatan/Xalacom and Macugen face generic competition. Generic latanoprost was launched in Japan in May 2010 and launches in other major markets followed. Xalatan lost exclusivity in the US in March 2011 and the company lost exclusivity for Xalatan and Xalacom in 15 major European markets in January 2012. www.visiongain.com Page 99
  • 30. Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024 Strengths Strong ophthalmic pipeline covering all major segments of the ophthalmic drugs market Strong presence in Asia-Pacific markets, especially Japan where it is market leader Weaknesses Vulnerable to generic competition for several products such as Hyalein and Cravit Opportunities Threats Competition in domestic and international markets Failure of pipeline candidates in clinical trials Expansion into US and European markets Greater penetration into the Chinese market Limited presence in the US and Europe Source: visiongain 2013 Santen has a well established history in the manufacture of ophthalmic drugs that dates back to over 120 years in the market. It remains the market leader in Japan in 2013. Santen has focused much of its marketing activity for ophthalmics on the domestic market and has entered copromotion agreements for some of its products in other markets. In 2010, for example, Santen entered into a co-promotion agreement with Banyu Pharmaceutical Co., Ltd. (currently MSD K.K.) regarding the glaucoma and ocular hypertension treatment Cosopt Combination Ophthalmic Solution. A number of pipeline products are also being developed in collaboration with partners in the US and elsewhere. The company has continued to grow and develop especially in the Asian markets with strong penetration throughout Asia including Korea and Hong Kong. Santen already enjoys a leading position in China’s prescription ophthalmic pharmaceutical market where the company began direct marketing its products in 2009 to further enhance its presence in that market. Moreover, Santen has also filed an application for manufacturing and marketing approval in China and has completed construction of a production plant in Suzhou, China. The company has a global vision and aims to become an international player in this sector. To make this happen, Santen will need to improve its presence in the US and European markets. In Europe, the acquisition of Novagali Pharma (now Santen S.A.S.) has helped to achieve this as well as bringing one marketed product and four pipeline candidates to the company. In the US, it was reported that in March 2013 Santen made substantial changes to the management structure of its US subsidiary, Santen Inc, supporting the idea that Santen is increasingly focusing on business activities in the US market. Santen’s pipeline is very strong compared to many of the industry leaders discussed in this report, with candidates in all major segments of the ophthalmic drugs market. Particularly notable, perhaps, are the recent launches of Diquas in Japan and South Korea, considering that Allergan’s www.visiongain.com Page 154

×